Table 3.

Maternal serum angiogenic factors levels at four time points during pregnancy by maternal blood pressure at 11–14 weeks in the NORA cohort

Angiogenic factors	Time points	Normal BP		Elevated BP			Hypertension (stage 1 and stage 2)
		N	Mean (95% CI)*	N	Mean (95% CI) *	P value†	N	Mean (95% CI)*	P value‡
sFlt-1 (pg/mL)	11–14 weeks	746	1585 (1549 to 1622)	98	1722 (1585 to 1862)	0.096	75	1758 (1585 to 1950)	0.079
	18–22 weeks	745	1698 (1660 to 1778)	98	1738 (1585 to 1950)	0.824	75	1905 (1698 to 2138)	0.139
	28–32 weeks	730	1660 (1585 to 1698)	92	1698 (1549 to 1862)	0.868	70	2042 (1820 to 2291)	0.001
	≥34 weeks	659	2570 (2512 to 2692)	82	2818 (2570 to 3162)	0.201	57	3311 (2951 to 3802)	0.000
PlGF (pg/mL)	11–14 weeks	746	37 (36 to 38)	98	35 (32 to 38)	0.243	75	35 (32 to 39)	0.593
	18–22 weeks	745	269 (257 to 275)	98	245 (224 to 269)	0.261	75	245 (219 to 275)	0.364
	28–32 weeks	730	617 (589 to 646)	92	575 (501 to 676)	0.718	70	537 (457 to 631)	0.270
	≥34 weeks	659	380 (355 to 398)	82	324 (269 to 380)	0.178	57	339 (275 to 427)	0.585
sFlt-1/PlGF ratio	11–14 weeks	746	42.7 (40.7 to 44.7)	98	50.1 (44.7 to 55.0)	0.013	75	50.1 (43.7 to 56.2)	0.042
	18–22 weeks	745	6.5 (6.2 to 6.8)	98	7.1 (6.3 to 7.9)	0.201	75	7.8 (6.8 to 8.9)	0.027
	28–32 weeks	730	2.7 (2.5 to 2.9)	92	2.9 (2.5 to 3.5)	0.643	70	3.8 (3.1 to 4.6)	0.005
	≥34 weeks	659	6.9 (6.3 to 7.4)	82	8.9 (6.9 to 11.2)	0.100	57	9.8 (7.4 to 13.2)	0.044

*Means (95% CI) were adjusted for maternal race, smoking during pregnancy, maternal body mass index at blood test and gestational weeks at blood test from models with logarithm-transformed serum angiogenic factors levels as outcomes; presented as geometric means.

†Statistically significant difference between normal BP and elevated BP groups.

‡Statistically significant difference between normal BP and hypertension group.

BP, blood pressure; PlGF, placental growth factor; sFlt-1, soluble fms-like tyrosine kinase 1.